FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer By Ogkologos - September 23, 2026 31 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR March is Colon Cancer Awareness Month March 11, 2021 How To Respond When Your Parents Are Critical Of Your Parenting... November 14, 2019 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... November 29, 2023 Load more HOT NEWS From athlete to wig-maker: how cancer changed Maria’s destiny Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer Unravelling the mystery of Barrett’s oesophagus
